EntryPoint Capital LLC bought a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 7,784 shares of the specialty pharmaceutical company’s stock, valued at approximately $92,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in shares of KalVista Pharmaceuticals by 28.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,482 shares of the specialty pharmaceutical company’s stock worth $43,000 after acquiring an additional 768 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth approximately $49,000. AJOVista LLC acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth approximately $60,000. Entropy Technologies LP acquired a new position in KalVista Pharmaceuticals during the first quarter worth approximately $121,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth approximately $126,000.
KalVista Pharmaceuticals Price Performance
Shares of KALV stock traded up $0.38 during midday trading on Friday, hitting $14.77. The company had a trading volume of 47,229 shares, compared to its average volume of 554,429. The company’s 50 day simple moving average is $12.34 and its 200 day simple moving average is $12.62. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.21 and a 52-week high of $16.88. The stock has a market cap of $631.27 million, a price-to-earnings ratio of -4.37 and a beta of 0.91.
Insider Buying and Selling at KalVista Pharmaceuticals
In related news, CEO Benjamin L. Palleiko sold 7,465 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $11.53, for a total value of $86,071.45. Following the sale, the chief executive officer now directly owns 224,547 shares in the company, valued at $2,589,026.91. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Benjamin L. Palleiko sold 7,465 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $11.53, for a total value of $86,071.45. Following the sale, the chief executive officer now directly owns 224,547 shares in the company, valued at $2,589,026.91. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Edward P. Feener sold 8,088 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.76, for a total value of $95,114.88. Following the completion of the sale, the insider now owns 72,858 shares in the company, valued at $856,810.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,512 shares of company stock worth $439,424. 12.30% of the stock is currently owned by insiders.
Analyst Ratings Changes
KALV has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday, July 15th. Needham & Company LLC cut their price target on KalVista Pharmaceuticals from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday, July 12th.
Get Our Latest Research Report on KALV
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
See Also
- Five stocks we like better than KalVista Pharmaceuticals
- Investing In Automotive Stocks
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Invest in Small Cap Stocks
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How to Evaluate a Stock Before Buying
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report).
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.